David Jeffrey Katz
Known title: EVP and General CounselCIK: 0001803966
Associated companies
Transaction History
| RDNT | ▲ Buy | Grant | 19,289 | $0 | 3/3/2026 | View on chart |
| RDNT | ▲ Buy | Option Exercise | 3,396 | $100K | 12/10/2025 | View on chart |
| RDNT | ▼ Sell | Open Market | 14,000 | $1.0M | 9/16/2025 | View on chart |
| RDNT | ▼ Sell | Gift | 4,593 | $0 | 9/11/2025 | View on chart |
| RDNT | ▼ Sell | Open Market | 17,000 | $1.2M | 8/13/2025 | View on chart |
| RDNT | ▲ Buy | Option Exercise | 15,423 | — | 3/10/2025 | View on chart |
| RDNT | ▲ Buy | Grant | 24,221 | $0 | 1/8/2025 | View on chart |
| RDNT | ▲ Buy | Option Exercise | 1,221 | — | 1/4/2025 | View on chart |
| RDNT | ▼ Sell | Open Market | 7,190 | $585K | 11/25/2024 | View on chart |
| RDNT | ▼ Sell | Open Market | 5,110 | $420K | 11/25/2024 | View on chart |
| RDNT | ▲ Buy | Option Exercise | 10,188 | $300K | 10/1/2024 | View on chart |
| RDNT | ▼ Sell | Gift | 1,640 | $0 | 8/14/2024 | View on chart |
| RDNT | ▼ Sell | Open Market | 16,400 | $1.0M | 6/7/2024 | View on chart |
| RDNT | ▲ Buy | Grant | 15,422 | $0 | 3/1/2024 | View on chart |
| RDNT | ▲ Buy | Option Exercise | 1,220 | — | 1/4/2024 | View on chart |
| RDNT | ▲ Buy | Grant | 18,256 | $0 | 1/4/2022 | View on chart |
| RDNT | ▲ Buy | Grant | 1,994 | $0 | 9/21/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 9, 2026
RadNet Q2 Earnings and AI Study News
RadNet received positive marks for its second-quarter testing and diagnostics services earnings. Additionally, a new study suggests DeepHealth AI could help avoid nearly one in five prostate biopsies. These developments provide context for the stock's current position within its 52-week range.
RadNet Q2 Earnings and AI Study News. RadNet received positive marks for its second-quarter testing and diagnostics services earnings. Additionally, a new study suggests DeepHealth AI could help avoid nearly one in five prostate biopsies. These developments provide context for the stock's current position within its 52-week range.